Eli Lilly has entered a multi-year agreement for global access to Evidation Health’s Andromeda platform that turns device-captured data into information on health and disease.
As part of the collaboration, Lilly will gain access to consented data gained from patients’ smartphones, connected sensors, wearables and their own voice.
Lilly plans to use the Andromeda platform to analyse the data and explore new approaches for the measurement and understanding of a patient’s health.
Eli Lilly chief digital officer Divakar Ramakrishnan said: “Digital health advancements, including mobile devices and wearables, have the potential to improve and personalise health outcomes.
“By leveraging Evidation’s Andromeda platform, Lilly’s scientists are gaining a deeper understanding of the physiological, environmental, and contextual indicators that can help shape future advancements in medicine and medicine delivery.”
With Andromeda, Lilly will be able to use Evidation-built algorithms to process raw data for use in clinical studies or to generate predictive models.
The algorithms are designed to turn complex, patient-generated behaviour data into new, quantifiable, and clinically meaningful information that can allow new ways to identify, treat and monitor diseases.
Lilly is using the Andromeda platform to assess data from continuous glucose monitors, insulin pumps and real-world information.
Data is intended to help improve the experience of diabetes patients and support Lilly’s efforts to create a connected ecosystem, including an automated insulin delivery device and connected pen.
Evidation Health co-founder and president Christine Lemke said: “Our initial collaborations with Lilly demonstrated that digital biomarkers can play a significant role in understanding individuals and disease, and we are excited to expand our collaboration.
“The data platform product embodies an industry-wide change to the way we measure health, which makes it more proactive, objective, and ultimately meaningful to individuals.”